Biopharmaceutical company fined for misleading investors

A Colorado-based biopharmaceutical company must pay more than $20 million for misleading investors about the efficacy of a lung cancer drug under development before raising $300 million in a public stock offering

from ABC News: Health https://ift.tt/2D9boGJ
via HEALTH